

11-09-04

IFW



PATENT
Customer No. 22,852
Attorney Docket No. 08702.0048-03000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
WOZNEY et al.,) Group Art Unit: 1646
)
Serial No.: 10/600,645) Examiner: Andres, Janet L.
)
Filed: June 23, 2003)
) Confirmation No.: 6135
For: RECEPTOR PROTEINS)
)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

RESPONSE TO RESTRICTION REQUIREMENT

In a restriction requirement dated October 8, 2004, the Examiner required
restriction under 35 U.S.C. § 121 between:

- Group I: Claims 1-2, 4, 6-8, 10-13, 18-19, 27, 29, 31 and 36, drawn to polynucleotides of SEQ ID NO:1 and means of expression;
- Group II: Claims 1-2, 4, 6-8, 10-13, 18-19, 27, 29, 32 and 36, drawn to polynucleotides of SEQ ID NO:3 and means of expression;
- Group III: Claims 1, 3, 5-6, 9, 18, 20-23, 27-29, 33 and 36, drawn to polynucleotides of SEQ ID NO:5;
- Group IV: Claims 1, 3, 5-6, 9, 18, 20-23, 27-29, 34 and 36, drawn to polynucleotides of SEQ ID NO:7;
- Group V: Claims 1, 3, 5-6, 9, 18, 20-23, 27-29 and 35-36, drawn to polynucleotides of SEQ ID NO:9;
- Group VI: Claims 14, 16 and 30, drawn to polypeptides of SEQ ID NO:2;

- Group VII: Claims 15, 17 and 30, drawn to polypeptides of SEQ ID NO:4;
- Group VIII: Claim 24, drawn to polypeptides of SEQ ID NO:6;
- Group IX: Claim 25, drawn to polypeptides of SEQ ID NO:8;
- Group X: Claim 26, drawn to polypeptides of SEQ ID NO:10;
- Group XI: Claims 37-38 and 41-42, drawn to antibody ligands for SEQ ID NO:5;
- Group XII: Claims 37, 39, 41 and 43, drawn to peptide ligands for SEQ ID NO:5;
- Group XIII: Claims 37, 40-41 and 44, drawn to organic molecule ligands for SEQ ID NO:5;
- Group XIV: Claims 37-38 and 41-42, drawn to antibody ligands for SEQ ID NO:7;
- Group XV: Claims 37, 39, 41 and 43, drawn to peptide ligands for SEQ ID NO:7;
- Group XVI: Claims 37, 40-41 and 44, drawn to organic molecule ligands for SEQ ID NO:7;
- Group XVII: Claims 37-38 and 41-42, drawn to antibody ligands for SEQ ID NO:9;
- Group XVIII: Claims 37, 39, 41 and 43, drawn to peptide ligands for SEQ ID NO:9;
- Group XIX: Claims 37, 40-41 and 44, drawn to organic molecule ligands for SEQ ID NO:9;
- Group XX: Claims 37-38, 46, 49-50, drawn to antibody ligands for SEQ ID NO:2;
- Group XXI: Claims 37, 39, 45, 47, and 49-50, drawn to peptide ligands for SEQ ID NO:2;
- Group XXII: Claims 37, 40, 45, 48-49 and 52, drawn to organic molecule ligands for SEQ ID NO:2;
- Group XXIII: Claims 37-38 and 46, drawn to antibody ligands for SEQ ID NO:4;

Group XXIV: Claims 37, 39, 45 and 47, drawn to peptide ligands for
SEQ ID NO:4; or

Group XXV: Claims 37, 40, 45 and 48, drawn to organic molecule ligands
for SEQ ID NO:4.

Applicants provisionally elect to prosecute Group I, Claims 1-2, 4, 6-8, 10-13,
18-19, 27, 29, 31 and 36, drawn to polynucleotides of SEQ ID NO:1 and means of
expression.

Please grant any extensions of time required to enter this response and charge
any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: November 8, 2004

By: Elizabeth E. McNamee
Elizabeth E. McNamee
Reg. No. 54,696



**CERTIFICATE UNDER 37 CFR § 1.10 OF
MAILING BY "EXPRESS MAIL"**

EV 446802636 US

USPS Express Mail Label Number

November 8, 2004

Date of Deposit

I hereby certify that this correspondence is being deposited with the United States Postal Services "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

By: Kathy Meuse
Kathy Meuse